文献速递瓣膜外科

快速释放瓣膜的早期与中期结果:Intuity意大利注册研究(INTU-ITA)

Early and Mid-Term Results of Rapid Deployment Valves: The Intuity Italian Registry (INTU-ITA).
PubMed 文献 · Ann Thorac Surg · 2018-07-25

该回顾性多中心注册研究纳入意大利20个中心2012年12月至2017年11月共902例接受快速释放生物瓣(RDB)置入的患者,评估早期与中期临床及血流动力学结果。器械成功率95.9%,30天全因死亡率2.8%,术后需永久起搏器植入63例(6.9%)。4年生存率为86%±1%,作者认为RDB可作为常规生物瓣的合理替代选择,尤其适用于微创与联合手术。

要点

  • 902例患者中器械成功率95.9%,30天全因死亡率为2.8%。
  • 术后需起搏器植入63例(6.9%),出院时主动脉瓣峰值与平均跨瓣压差分别为19±7 mm Hg和11±4 mm Hg。
  • 4年生存率为86%±1%,术前传导障碍与既往心肌梗死史为死亡的独立相关因素。

核心结论

  • 主动脉快速释放生物瓣提供良好的早期与中期临床及血流动力学结果,作者认为该装置可作为常规生物瓣的合理替代选择,尤其适用于微创与联合手术。

研究设计与样本

  • 回顾性多中心研究,分析意大利全国注册研究中接受单独或联合主动脉瓣置换的902例患者数据,采用欧洲心脏手术风险评估系统定义术前变量、采用瓣膜学术研究联盟更新定义评估术后结局,随访行临床与超声心动图检查或电话访谈,采用Kaplan-Meier法进行生存分析。

主要发现

  • 器械成功率为95.9%,30天全因死亡率为2.8%。
  • 术后需起搏器植入63例(6.9%)。
  • 出院时主动脉瓣峰值跨瓣压差为19±7 mm Hg,平均跨瓣压差为11±4 mm Hg。
  • 轻度主动脉瓣反流71例(8.2%),中度主动脉瓣反流10例(1.2%)。
  • 中位随访时间357天(四分位距103至638天),4年生存率为86%±1%。

关键数值与推荐

  • 术前传导障碍与既往心肌梗死史与死亡独立相关。

临床怎么用

  • 作者认为快速释放生物瓣可作为常规生物瓣的合理替代选择,尤其适用于微创与联合手术。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Rapid deployment bioprostheses (RDBs) have been recently introduced into clinical practice for the treatment of severe aortic valve stenosis. The aim of this retrospective multicenter study was to assess early and mid-term clinical and hemodynamic outcomes of patients undergoing RDB implantation. METHODS: Data from a national registry that included patients who underwent isolated or combined aortic valve replacement with RDB in Italy were analyzed. Definitions of the European System for Cardiac Operative Risk Evaluation were used for preoperative variables and updated definitions from the Valve Academic Research Consortium were used for postoperative outcomes assessment. Univariable and multivariable analyses were performed to identify independent predictors of mortality. Follow-up was performed with clinical and echocardiographic examinations at each study site and, if this was not possible, through telephonic interviews. The Kaplan-Meier method was used for survival analysis. RESULTS: A total of 902 patients (December 2012 through November 2017) from 20 national centers were included in the registry. Device success was 95.9%, and 30-day all-cause mortality was 2.8%. Postoperative pacemaker implantation was needed in 63 patients (6.9%). At discharge, peak and mean transaortic gradients were 19 ± 7 mm Hg and 11 ± 4 mm Hg, respectively. Mild and moderate aortic regurgitation were found in 71 patients (8.2%) and in 10 patients (1.2%), respectively. Median follow-up time was 357 days (interquartile range: 103 to 638 days). Survival at 4 years was 86% ± 1%. Preoperative conduction disturbances and history of previous myocardial infarction were independently associated with mortality. CONCLUSIONS: Aortic RDBs provide good early and mid-term clinical and hemodynamic outcomes. These devices may be considered as a reasonable alternative to conventional bioprostheses, especially in minimally invasive and combined operations.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. D'Onofrio A, Tessari C, Filippini C, et al. Early and Mid-Term Results of Rapid Deployment Valves: The Intuity Italian Registry (INTU-ITA). Ann Thorac Surg. 2018. PMID: 30055145. doi:10.1016/j.athoracsur.2018.07.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。